CP
EW icon

Corbenic Partners’s Edwards Lifesciences EW Stock Holding History

Corbenic Partners’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$4K Hold
45
– – ﹤0.01% 162
2022
Q1 		$5K Buy
+45
New +$5.05K ﹤0.01% 178

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Corbenic Partners's EW Position: Q2 2022 in Review

Corbenic Partners held its Edwards Lifesciences (EW) position steady in Q2 2022 at 45 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #162.

Corbenic Partners first reported a position in EW in Q1 2022 and has held it in 2 quarters since. The position peaked at $5K in Q1 2022. 1,272 funds tracked by Wall St. Rank hold EW as of Q2 2022.

  • Corbenic Partners held 45 shares of Edwards Lifesciences worth $4K as of Q2 2022.
  • Corbenic Partners left its Edwards Lifesciences share count unchanged in Q2 2022.
  • Edwards Lifesciences made up ﹤0.01% of Corbenic Partners's portfolio in Q2 2022, its #162 holding.
  • Corbenic Partners first reported a position in Edwards Lifesciences in Q1 2022 and has held it in 2 quarters since.
  • Corbenic Partners's Edwards Lifesciences position peaked at $5K in Q1 2022.
  • 1,272 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2022.

Based on Corbenic Partners's 13F filing for Q2 2022, filed 25 Jul 2022.